Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

LocanaBio

Main focus: Next-generation editing of RNA to treat genetic diseases

Company stage: Pre-clinical

Diseases: amyotrophic lateral sclerosis (ALS), myotonic dystrophy type 1 (DM1), Huntingtons disease, retinal diseases

Genome editing tool: CRISPR-Cas13d

Funding stage: Private

Location: San Diego, CA, USA

Website: https://locanabio.com/

Pipeline: https://locanabio.com/pipeline/

LocanaBio is developing next-generation RNA-editing technologies, applying its proprietary CRISPR-based CORRECTX™ platform to do so. The company focuses on neuromuscular, neurodegenerative and ophthalmologic diseases, with multiple pre-clinical programmes currently under development.

Tags

HashtagLocanaBio

Company: LocanaBio
close
Search CRISPR Medicine